From: Rituximab for auto-immune alveolar proteinosis, a real life cohort study
Patients | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Age (year) | 44 | 56 | 50 | 30 | 53 | 41 | 49 | 44 | 59 | 41 | 51 | 49 | 45 |
Gender | M | M | M | F | M | F | M | F | F | M | M | M | M |
Duration of PAP (months) | 38 | 12 | 12 | 29 | 64 | 50 | 6 | 32 | 9 | 15 | 45 | 20 | 51 |
Smoking status | Never | Never | Current | Current | Never | Never | Never | Never | Ex | Current | Ex | Ex | Current |
Inhaled toxic | No | No | Yes | Yes | Yes | No | Yes | No | Yes | Yes | Yes | Yes | No |
Previous therapy | No | WLL GM-CSF | WLL | WLL | WLL GM-CSF | WLL GM-CSF | No | WLL GM-CSF | WLL | WLL | WLL GM-CSF | WLL | No |
Initial Improvement with WLL | Np | No | No | Yes | Yes | Yes | Np | Yes | No | No | No | Yes | Np |
Aggravation in the 3Â month before RTX | Yes | No | Yes | Yes | No | Yes | Yes | No | Yes | Yes | Yes | Yes | Yes |
Disease severity score | 3 | 2 | 2 | 2 | 2 | 4 | 3 | 4 | 2 | 2 | 3 | 2 | 3 |
Anti GM-CSF titer before RTX | 10,000 | 480 | 400 | 700 | 1000 | 200 | 400 | 400 | 40 | 300 | 300 | 800 | 4000 |
D(a-A)O2 | |||||||||||||
At RTX injection | 36 | 36 | 40 | 38 | 31 | 50 | 46 | 57 | 37 | 35 | 47 | 35 | 40 |
At M12 | 20 | 32 | 60 | 51 | 30 | Na | 35 | 60 | 38 | Na | 15 | 26 | 27 |